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ABSTRACT (Maximum 200 Words)
Elevated serum levels of insulin-like growth factor 1 (IGFl) have been found in prostate cancer patients, and IGFl-related signal transduction is thought to be an important factor in the development of prostate cancers. The goals of this project are to discover small organic molecules that suppress IGF-activated prostate cancers by cell-based screening and to analyze their action mechanisms. In the first year of funding, we discovered, from our collection of synthetic compounds, the drug-like compound we call 125B11 that suppress IGFl-dependent growth of prostate cancer cells but not serum-dependent growth. During this period of funding, we analyzed the mechanism of action of 125B11 to gain molecular insights into how IGF1 stimulates the growth of prostate cancer cells. DNA microarray and cell biological experiments indicated that 125B11 modulates the function of sterol regulatory element binding protein (SREBP), a transcription factor that activates specific genes involved in cholesterol synthesis, endocytosis of low density lipoproteins, and the synthesis of both saturated and unsaturated fatty acids. Chemical genetics of 125BIl may reveal a novel crosstalk between fatty acid metabolism and prostate cancer progression. To analyze mechanism of action ot • 80 125B11 "0
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In the first year of funding, we discovered 
Microarray experiments of 125B1l
Gene expression profiling comparison in the drug-treated and -untreated cells by DNA microarray technology might reveal specific molecular pathways affected by the drugs. DU145 prostate cancer cells were treated with 125B 11 or DMSO alone in the presence of IGF 1, and extracted mRNA was analyzed by Affimetrix DNA micoarrays at the Microarray Facility in Baylor College of Medicine. To our surprise, we found that the genes downregulated by 125B 11 included those known or likely to be controlled by sterol regulatory element binding protein (SREBP), a transcription factor that activates specific genes involved in cholesterol synthesis, endocytosis of low density lipoproteins, and the synthesis of both saturated and unsaturated fatty acids (3). These include LDL receptor and HMG-CoA reductase, a target of cholesterollowering drug statins. We hypothesized that 125B 11, whether directly or indirectly, inhibits SREBP or its pathway. 
Met88opretehnas
We examined if the Fig. 2 Regulation of SREBP by sterols. cleavage of SREBP is blocked by 125B1 1 in cells. Western blot analysis showed that treatment with 5 gM of 125Bl 1 increased the amounts of uncleaved 125Kda SREBP (Fig. 3) 
Conclusion
There is no change in Tasks and experimental design. As originally planned, discovery of 125B 11 in the first year of funding enabled its mechanistic analysis in the second year. Our analysis indicated the potential role of SREBP in IGF1-dependent growth of prostate cancers. Continued experiments may reveal a molecular understanding of the relationship between cholesterol metabolism and prostate cancer progression. We are also interested in understanding how 125B1 1 blocks the cleavage of SREBP. Such studies may lead to the discovery of a new drug target.
